High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma-Reference-Cited by-同舟云学术

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma

Published:2016-09 Issue:10 Volume:107 Page:1458-1464
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Akiyama Hiroki¹,Takase Hiroshi²,Kubo Fumito³,Miki Tohru⁴,Yamamoto Masahide¹,Tomita Makoto⁵,Mochizuki Manabu²,Miura Osamu¹,Arai Ayako¹

Affiliation:

1. Department of Hematology Tokyo Medical and Dental University Tokyo Japan

2. Department of Ophthalmology and Visual Science Tokyo Medical and Dental University Tokyo Japan

3. Department of Internal Medicine Tokyo Adventist Hospital Tokyo Japan

4. Department of Internal Medicine Flowers and Forest Tokyo Hospital Tokyo Japan

5. Clinical Research Center Medical Hospital of Tokyo Medical and Dental University Tokyo Japan

Funder

Ministry of Education, Culture, Sports, Science, and Technology

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13012

Reference24 articles.

1. Intraocular Lymphoma

2. High‐resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays

3. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features

4. Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid

5. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoarchitectonics of CTAB-modified kanemite as carrier of methotrexate;Applied Clay Science;2024-03

2. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma;British Journal of Haematology;2023-12-22

3. Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis;BMC Ophthalmology;2023-11-22

4. Fluorescent drug delivery system used for methotrexate and its inhibition against HepG2 cells;Journal of the Iranian Chemical Society;2023-10-09

5. Primary Autologous Stem Cell Transplantation for Unilateral Primary Central Nervous System Lymphoma–Ophthalmic Variant (Primary Vitreoretinal Lymphoma);Journal of VitreoRetinal Diseases;2023-06-05